Asia-Pacific Insulin Delivery Devices Market Size (2024 - 2029)

Asia-Pacific Insulin Delivery Devices Market Analysis

The Asia-Pacific Insulin Delivery Devices Market size is estimated at USD 18.88 billion in 2024, and is expected to reach USD 21.55 billion by 2029, growing at a CAGR of greater than 2.68% during the forecast period (2024-2029).

The occurrence of newly detected cases of Type 1 and Type 2 diabetes is observed to be on the rise, primarily attributed to factors such as obesity, unhealthy eating habits, and lack of physical activity. 

The escalating number of individuals diagnosed with diabetes and the subsequent increase in healthcare expenses in developed nations serve as clear indicators of the growing utilization of diabetic care products. Furthermore, the market growth is propelled by the surging adoption of insulin-delivery devices and the expanding prevalence of diabetes. Prominent manufacturers are directing their efforts towards technological advancements and the creation of cutting-edge products in order to secure a significant market share.

According to the International Diabetes Federation (IDF), the IDF South-East Asia (SEA) Region is home to 90 million adults (aged 20-79) living with diabetes in 2021. This number is projected to rise to 152 million by 2045. In the IDF Western Pacific Region, there are currently 206 million adults (aged 20-79) living with diabetes in 2021, and this is expected to increase to 260 million by 2045. 

The primary cause of diabetes is the imbalance in blood glucose levels, which deviate from the standard levels. Physicians can diagnose the disease through general lab diagnostic tests. However, individuals with greater fluctuations in glucose levels should monitor their levels daily. Those who require insulin must frequently check their blood glucose levels, adjust insulin doses, or consider changing their medication if necessary.

The Asia-Pacific region has witnessed an astounding increase in the prevalence of diabetes in patients, in recent years. The increasing demand for insulin has led to great R&D in manufacturing different, painless types of insulin deliverable devices, like CGM-integrated insulin pumps. Traditionally, insulin syringes were the only form of insulin delivery system, which were considered to be painful and not user-friendly. Furthermore, the dosage may not be accurate. Thus, companies, like Novo Nordisk and Sanofi, among others, have bought their insulin pens in the market. These pens have a specific set of dosages and are considered to be not only less painful to use, but also reduce wastage of insulin. The high cost of insulin pens is the only prominent restraining factor for the growth of the pens market.

Asia-Pacific Insulin Delivery Devices Industry Segmentation

Insulin injections under the skin are the most popular method of administering insulin. Insulin can be administered subcutaneously using various devices, including insulin pens, pumps, vials, and syringes. The study provides a detailed analysis of the insulin delivery devices market in the Asia-Pacific region and includes market share, size, forecast, and industry overview. Asia-Pacific Insulin Delivery Devices Market is segmented by devices (Insulin Pens (cartridges in reusable insulin pens, and disposable insulin pens), insulin syringes, insulin jet injectors, insulin pumps (Technology ( Tethered Insulin Pump, Tubeless Insulin Pump) and by Components (insulin pump device, insulin pump reservoir, and infusion set). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.